Short answer. Non-dilutive financing lets a SaaS startup raise growth capital without giving up equity. The main routes in 2026 are revenue-based financing, venture debt, MRR or AR-backed credit lines, and grants. Each repays differently and fits a different stage, but all keep founders in control of the company.
For most of the last decade, the default answer to "how do we fund growth?" was a venture round. Sell a slice of the company, take the cash, repeat. That reflex made sense when money was cheap and the only scarce resource was ambition. It makes far less sense for a SaaS business with predictable revenue, where selling equity to fund repeatable growth spend is close to the most expensive financing a founder can choose.
The alternatives have grown up. There is now a whole category of capital built specifically for recurring-revenue businesses, and a founder in 2026 has real choices that keep the cap table intact. This playbook maps those options, explains what each one actually costs, and gives a simple way to pick the right one for your stage and your numbers.
What is non-dilutive financing?
Non-dilutive financing is any capital you raise without giving up equity or ownership. Instead of selling shares, you borrow against assets or future revenue and repay over time. The founder keeps full control, the existing shareholders keep their stake, and the cost is a defined fee or interest rate rather than a permanent slice of every future dollar the company earns. For SaaS, the "asset" being financed is usually the predictable stream of subscription revenue, or the customers that produce it.
Why SaaS is built for non-dilutive capital
Subscription businesses have a quality lenders love: their revenue is contracted, recurring, and easy to verify. A lender can look at your monthly recurring revenue, your churn, and your retention curve and underwrite a facility with real confidence, because next month's revenue is mostly already on the books. Add high gross margins and the picture gets even better. That predictability is exactly why a category of SaaS-specific financing exists at all, and why the terms have become genuinely competitive rather than the punitive deals founders used to settle for.
The non-dilutive options at a glance
Five instruments cover most of the field. Here is how they compare.
| Option | How it works | Headline cost | Dilution | Best for |
|---|---|---|---|---|
| Revenue-based financing | Advance repaid as a fixed share of monthly revenue until a cap | 1.3x-2.5x cap, or 5%-15% flat fee | None | Steady, repeatable spend; early revenue to Series A |
| Venture debt | Term loan with warrants, usually alongside a VC round | ~10%-14% interest plus warrants | Small (warrants) | Runway between priced rounds, post Series A |
| CAC-financing | Funds acquisition spend against the recurring revenue it produces | Priced to your CAC payback | None | Scaling proven acquisition; Series A/B with clean cohorts |
| Term loan / line of credit | Traditional bank debt or revolving working capital | Interest, often with covenants | None | Established revenue, smoothing cash flow |
| Grants (e.g. SBIR) | Non-repayable funding for qualifying work | Free, but slow and restricted | None | R&D-heavy work that fits the grant criteria |
| Merchant cash advance | Lump sum repaid from a slice of daily or weekly receipts | Factor 1.1x-1.5x; high effective APR | None | Short-term gaps only; use with caution |
| R&D tax credits | Cash rebate on qualifying research and development spend | Free, claimed in arrears | None | R&D-heavy teams in eligible jurisdictions |
| Crowdfunding | Pre-sales (rewards) or a community raise | Platform fees; equity if equity-crowdfunding | None (rewards) / Yes (equity) | Consumer or community-driven products |
The first three are where most SaaS founders spend their time, and they reward a closer look. We compare them head-to-head, including the real cost math, in our guide to revenue-based financing versus venture debt versus CAC-financing.
Revenue-based financing
Revenue-based financing (RBF) advances capital and takes repayment as a fixed percentage of your monthly revenue until you have returned the principal plus a flat fee. Payments flex with your revenue, there are no warrants, and underwriting is fast because it keys off your MRR feed. The one catch worth knowing: because the fee is a fixed dollar amount, repaying quickly makes its true annualised cost climb, so RBF fits steady, repeatable spend better than a once-in-a-company growth sprint.
Venture debt
Venture debt is a term loan for companies that have already raised institutional equity. It carries a fixed interest rate, often an interest-only period followed by amortisation, and almost always includes warrants, the right to buy a small amount of stock later. That makes it not quite fully non-dilutive, but the dilution is a fraction of an equity round. It works best as a runway extender between priced rounds, with one caveat: the covenants and fixed payments bite hardest in a weak quarter, so it suits founders who are confident they will not need the lender's patience.
CAC-financing
CAC-financing starts from a different question: not how much revenue you have or who backs you, but what a dollar of acquisition spend turns into and how reliably. For a business with strong retention, customer acquisition behaves like a capital expenditure, an investment that pays back over the life of the customer. CAC-financing funds that spend against the future revenue it produces, with pricing tied to your unit economics rather than a blanket multiple. We explain the thinking behind it, including how to read acquisition as an asset, in our piece on the EBITCAC framework.
Grants and credit lines
Two options round out the toolkit. Grants, such as R&D credits and government innovation schemes, are genuinely free money, but they are slow to secure, restricted to qualifying work, and rarely large enough to fund growth on their own. Lines of credit and traditional term loans, meanwhile, suit companies with established revenue that need to smooth working capital rather than pour fuel on acquisition. Neither is a growth engine, but both have a place in a well-built capital stack.
Merchant cash advances and crowdfunding
Two more options sit at the edges of the toolkit. A merchant cash advance hands over a lump sum repaid from a slice of daily or weekly receipts; it is fast and needs no collateral, but the factor rate of 1.1x to 1.5x can translate into an effective annual cost well above 50%, so it suits short-term gaps and little else. Treat it as emergency liquidity, not growth capital.
Crowdfunding splits into two very different things. Rewards or pre-sale campaigns raise money from customers in exchange for early product, taking only platform fees and no equity, which makes them genuinely non-dilutive and a useful demand test. Equity crowdfunding, by contrast, does sell shares and is dilutive. For founders weighing the community route, our guide to crowdfunding for startups covers when each model makes sense.
How to choose: match the instrument to your stage and unit economics
The right choice follows from two numbers, not from whichever provider emails you first: how long a customer takes to pay back their acquisition cost, and how much of that revenue survives a year. With a CAC payback inside roughly twelve to eighteen months and net revenue retention comfortably above 90%, your growth spend is a high-quality asset, and RBF or CAC-financing lets you scale it without touching the cap table. If you have institutional backing and a round on the horizon, venture debt is the cheapest way to buy runway to it. And if your data is still thin and product-market fit is forming, none of these is a substitute for equity.
The strongest operators rarely pick just one. They raise equity for the genuinely unfinanceable work, layer debt for runway, and fund the predictable growth spend with revenue- or CAC-based capital. For the full decision math and how to stack these across Series A and B, see our comparison guide.
Match the instrument to your stage
The right tool depends less on what a provider is selling than on where your company sits. This is the shortcut.
| Stage | Typical numbers | Best-fit instruments |
|---|---|---|
| Pre-revenue / idea | Little or no recurring revenue | Grants, R&D tax credits, and equity; the revenue-based tools do not fit yet |
| Early (MRR $25k-$100k) | Gross margin above 60%, some retention history | Revenue-based financing; MCA only for short gaps |
| Growth (Series A, ARR $1M-$10M) | NRR above 100%, CAC payback under 18 months | RBF, CAC-financing, and venture debt alongside a round |
| Scale (Series B+, ARR $10M+) | Predictable cohorts, gross margin 70%-85% | Venture debt, CAC-financing, credit lines, and a customer value fund |
A four-question framework for choosing
When the options blur together, four questions usually settle it.
- How predictable is your revenue? The steadier your MRR and retention, the more a lender will advance and the cheaper the terms.
- How long is your CAC payback? Under 12 to 18 months, growth spend is financeable as an asset; beyond 24, most lenders price it harshly or decline.
- Do you have a round on the horizon? If institutional equity is coming, venture debt is the cheapest way to extend runway to it.
- Is the work itself financeable? Genuinely unproven, high-risk R&D is what equity is for; predictable, repeatable spend is what debt and revenue-based capital are for.
Non-dilutive versus equity: the dilution math
The reason this matters is that equity is almost always the most expensive money on the table. Suppose you need $1 million to fund a year of proven growth spend. Raised as equity at a $10 million post-money valuation, that is 10% of your company; if the business is worth $100 million at exit, that slice cost you $10 million. The same $1 million as revenue-based financing at a 1.4x cap costs $400,000 in total, and you keep the 10%. Equity only wins when the spend is too risky to finance any other way, which is exactly the test the four questions above are built to apply.
Frequently asked questions
What does non-dilutive financing mean? It means raising capital without selling equity. You borrow against assets or future revenue and repay with a fee or interest, so ownership and control stay where they are.
Is non-dilutive financing cheaper than raising equity? For predictable, repeatable spend, almost always. Equity is the most expensive capital a founder can raise, because you pay for it with a permanent share of all future value. Debt or revenue-based capital has a defined, finite cost. The exception is genuinely high-risk, unprovable work, which equity is still best suited to fund.
What CAC payback and retention do I need to qualify? As a rough guide, a CAC payback inside twelve to eighteen months and net revenue retention above 90% put you in strong shape for revenue- and CAC-based options. The tighter and more predictable your numbers, the better the terms.
Can I combine several options? Yes, and most growth-stage companies do. Equity, venture debt, and revenue- or CAC-based financing each cover a different layer of risk, and the art is sequencing them so the cap table only pays for the risk that cannot be financed any other way.
